Loading...
•
Mar 31, 2023
Acumen Q1 2023 Earnings Report
Reported financial results for the first quarter of 2023 and provided a business update.
Key Takeaways
Acumen Pharmaceuticals reported a net loss of $11.3 million for the first quarter of 2023. As of March 31, 2023, cash, cash equivalents and marketable securities totaled $183.8 million.
Focused on executing the Phase I INTERCEPT-AD trial of ACU193.
Expect to report topline results from INTERCEPT-AD in the third quarter of 2023.
Cash, cash equivalents and marketable securities of $183.8 million as of March 31, 2023 expected to be sufficient to support clinical and operational activities through 2025.
Presented research at the International Conference on Alzheimer’s and Parkinson’s Diseases (ADPD) in March 2023.
Forward Guidance
Acumen expects to report topline results from the Phase 1 INTERCEPT-AD trial in the third quarter of 2023 and anticipates interaction with the FDA in the fourth quarter to inform the next phase of development for ACU193.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...